{"entity":{"type":"insider","cik":"0001769651","url":"/insider/0001769651","json_url":"/insider/0001769651.json","name":"Fairmount Healthcare Fund II L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":18,"n_filings":16,"first":"2021-09-23","last":"2026-07-20","span_basis":"filed_date"},"name_variants":[{"name":"Fairmount Healthcare Fund II L.P.","source":"filing","n_filings":16,"first_seen":"2021-09-23","last_seen":"2026-07-20"}],"transactions":[{"id":6226977,"accession":"0001104659-26-085113","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-085113","line_url":"/filing/0001104659-26-085113#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"CRESCENT BIOPHARMA, INC.","issuer_ticker":"CBIO","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas; Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":853450.0,"shares_display":"853,450","price_per_share":14.5,"price_display":"14.50","price_state":"stated","total_value":12375025.0,"total_display":"12,375,025.00","shares_owned_after":3601316.0,"shares_owned_after_display":"3,601,316","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-16","filed_date":"2026-07-20","scope":"insider"},{"id":5976645,"accession":"0001104659-26-080009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-080009","line_url":"/filing/0001104659-26-080009#line-2","is_derivative":false,"issuer_cik":"0000907654","issuer_name":"Oruka Therapeutics, Inc.","issuer_ticker":"ORKA","issuer_name_source":null,"issuer_url":"/issuer/0000907654","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Fairmount Healthcare Co-Invest III L.P.; Harwin Peter Evan; Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3553410.0,"shares_display":"3,553,410","price_per_share":84.43,"price_display":"84.43","price_state":"stated","total_value":300014406.3,"total_display":"300,014,406.30","shares_owned_after":1131954.0,"shares_owned_after_display":"1,131,954","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-01","scope":"insider"},{"id":6109801,"accession":"0001104659-26-076967","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-26-076967","line_url":"/filing/0001104659-26-076967#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":null,"owner_name":"Kiselak Tomas; Harwin Peter Evan; Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.","owner_url":null,"role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4684781.0,"shares_display":"4,684,781","price_per_share":85.31,"price_display":"85.31","price_state":"stated","total_value":399658667.11,"total_display":"399,658,667.11","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-23","filed_date":"2026-06-23","scope":"insider"},{"id":5942597,"accession":"0001104659-26-060294","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-060294","line_url":"/filing/0001104659-26-060294#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.; Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1176470.0,"shares_display":"1,176,470","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":19999990.0,"total_display":"19,999,990.00","shares_owned_after":5090928.0,"shares_owned_after_display":"5,090,928","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-11","filed_date":"2026-05-13","scope":"insider"},{"id":6226375,"accession":"0001104659-26-038546","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-038546","line_url":"/filing/0001104659-26-038546#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Harwin Peter Evan; Fairmount Healthcare Fund II L.P.; Kiselak Tomas","owner_url":null,"role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","shares_owned_after":2359025.0,"shares_owned_after_display":"2,359,025","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-04-01","scope":"insider"},{"id":6084888,"accession":"0001104659-26-005921","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-005921","line_url":"/filing/0001104659-26-005921#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Harwin Peter Evan; Fairmount Healthcare Fund II L.P.; Kiselak Tomas","owner_url":null,"role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1750000.0,"shares_display":"1,750,000","price_per_share":76.3,"price_display":"76.30","price_state":"stated","total_value":133525000.0,"total_display":"133,525,000.00","shares_owned_after":298647.0,"shares_owned_after_display":"298,647","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-22","filed_date":"2026-01-22","scope":"insider"},{"id":4923420,"accession":"0001104659-25-119320","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-119320","line_url":"/filing/0001104659-25-119320#line-1","is_derivative":false,"issuer_cik":"0001253689","issuer_name":"CRESCENT BIOPHARMA, INC.","issuer_ticker":"CBIO","issuer_name_source":null,"issuer_url":"/issuer/0001253689","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas; Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Ordinary Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1360000.0,"shares_display":"1,360,000","price_per_share":13.41,"price_display":"13.41","price_state":"stated","total_value":18237600.0,"total_display":"18,237,600.00","shares_owned_after":2747866.0,"shares_owned_after_display":"2,747,866","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-04","filed_date":"2025-12-08","scope":"insider"},{"id":5207209,"accession":"0001104659-25-102606","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-102606","line_url":"/filing/0001104659-25-102606#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Fund II GP LLC; Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":454545.0,"shares_display":"454,545","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","shares_owned_after":3914458.0,"shares_owned_after_display":"3,914,458","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-23","filed_date":"2025-10-27","scope":"insider"},{"id":4112271,"accession":"0001104659-25-098362","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-098362","line_url":"/filing/0001104659-25-098362#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak Tomas","owner_url":null,"role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":316219.0,"shares_display":"316,219","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":6008161.0,"total_display":"6,008,161.00","shares_owned_after":2209025.0,"shares_owned_after_display":"2,209,025","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-07","filed_date":"2025-10-09","scope":"insider"},{"id":9223900,"accession":"0001104659-24-100766","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-100766","line_url":"/filing/0001104659-24-100766#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas","owner_url":null,"role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":5100000.0,"total_display":"5,100,000.00","shares_owned_after":1892806.0,"shares_owned_after_display":"1,892,806","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-17","scope":"insider"},{"id":2837663,"accession":"0001104659-24-100330","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001104659-24-100330","line_url":"/filing/0001104659-24-100330#line-5","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Harwin Peter Evan; Fairmount Funds Management LLC; Kiselak Tomas; Fairmount Healthcare Fund II L.P.","owner_url":null,"role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300000.0,"shares_display":"300,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":5100000.0,"total_display":"5,100,000.00","shares_owned_after":1604891.0,"shares_owned_after_display":"1,604,891","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-16","scope":"insider"},{"id":2129489,"accession":"0001104659-24-100769","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-100769","line_url":"/filing/0001104659-24-100769#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.; Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1600000.0,"shares_display":"1,600,000","price_per_share":18.75,"price_display":"18.75","price_state":"stated","total_value":30000000.0,"total_display":"30,000,000.00","shares_owned_after":3445813.0,"shares_owned_after_display":"3,445,813","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-13","filed_date":"2024-09-17","scope":"insider"},{"id":2080400,"accession":"0000950170-24-007123","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-007123","line_url":"/filing/0000950170-24-007123#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":null,"owner_name":"Fairmount Funds Management LLC; Fairmount Healthcare Fund GP LLC; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Fund L.P.","owner_url":null,"role":"Director, Ten percent owner, Other","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":476190.0,"shares_display":"476,190","price_per_share":21.0,"price_display":"21.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","shares_owned_after":1839954.0,"shares_owned_after_display":"1,839,954","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-22","filed_date":"2024-01-24","scope":"insider"},{"id":7844257,"accession":"0001104659-23-081729","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-23-081729","line_url":"/filing/0001104659-23-081729#line-3","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Healthcare Fund L.P.; Harwin Peter Evan; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest II L.P.; Fairmount Funds Management LLC; Kiselak Tomas","owner_url":null,"role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1992734.0,"shares_display":"1,992,734","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":33876478.0,"total_display":"33,876,478.00","shares_owned_after":1992734.0,"shares_owned_after_display":"1,992,734","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-13","filed_date":"2023-07-17","scope":"insider"},{"id":7844253,"accession":"0001104659-23-081729","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-23-081729","line_url":"/filing/0001104659-23-081729#line-2","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Healthcare Fund L.P.; Harwin Peter Evan; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest II L.P.; Fairmount Funds Management LLC; Kiselak Tomas","owner_url":null,"role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":892529.0,"shares_display":"892,529","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":15172993.0,"total_display":"15,172,993.00","shares_owned_after":892529.0,"shares_owned_after_display":"892,529","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-13","filed_date":"2023-07-17","scope":"insider"},{"id":7844250,"accession":"0001104659-23-081729","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-081729","line_url":"/filing/0001104659-23-081729#line-1","is_derivative":false,"issuer_cik":"0001663607","issuer_name":"Apogee Therapeutics, Inc.","issuer_ticker":"APGE","issuer_name_source":null,"issuer_url":"/issuer/0001663607","owner_cik":null,"owner_name":"Fairmount Healthcare Fund L.P.; Harwin Peter Evan; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Co-Invest II L.P.; Fairmount Funds Management LLC; Kiselak Tomas","owner_url":null,"role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55913.0,"shares_display":"55,913","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":950521.0,"total_display":"950,521.00","shares_owned_after":55913.0,"shares_owned_after_display":"55,913","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-13","filed_date":"2023-07-17","scope":"insider"},{"id":6718455,"accession":"0001104659-22-092992","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-092992","line_url":"/filing/0001104659-22-092992#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Fund L.P.; Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund GP LLC; Fairmount Funds Management LLC","owner_url":null,"role":"Director, Ten percent owner, Other","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":425531.0,"shares_display":"425,531","price_per_share":23.5,"price_display":"23.50","price_state":"stated","total_value":9999978.5,"total_display":"9,999,978.50","shares_owned_after":1363764.0,"shares_owned_after_display":"1,363,764","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-17","filed_date":"2022-08-19","scope":"insider"},{"id":4123299,"accession":"0000899243-21-037255","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-037255","line_url":"/filing/0000899243-21-037255#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":null,"owner_name":"Fairmount Healthcare Fund II GP LLC; Fairmount Healthcare Fund II L.P.; Fairmount Healthcare Fund L.P.; Fairmount Funds Management LLC; Fairmount Healthcare Fund GP LLC","owner_url":null,"role":"Director, Ten percent owner, Other","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":909000.0,"shares_display":"909,000","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":9999000.0,"total_display":"9,999,000.00","shares_owned_after":938233.0,"shares_owned_after_display":"938,233","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-21","filed_date":"2021-09-23","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001253689","name":"CRESCENT BIOPHARMA, INC.","url":"/issuer/0001253689","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2025-12-08","last_seen":"2026-07-20"},{"type":"issuer","type_label":"ISSUER","cik":"0000907654","name":"Oruka Therapeutics, Inc.","url":"/issuer/0000907654","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2026-07-01","last_seen":"2026-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001636282","name":"Spyre Therapeutics, Inc.","url":"/issuer/0001636282","role":"Director","n_filings":1,"first_seen":"2026-06-23","last_seen":"2026-06-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001590750","name":"Viridian Therapeutics, Inc.\\DE","url":"/issuer/0001590750","role":"Director, Ten percent owner, Other","n_filings":6,"first_seen":"2021-09-23","last_seen":"2026-05-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001953926","name":"Zenas BioPharma, Inc.","url":"/issuer/0001953926","role":"Director","n_filings":4,"first_seen":"2024-09-16","last_seen":"2026-04-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001974640","name":"Apogee Therapeutics, Inc.","url":"/issuer/0001974640","role":"Director","n_filings":2,"first_seen":"2023-07-17","last_seen":"2026-01-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001769651","retrieved_at":"2026-08-21T01:29:53+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-19","last_ingest":"2026-08-20T05:22:56.381658+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}